Allstate Investment Management’s Charles River Laboratories CRL Stock Holding History

Allstate Investment Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$272K	Buy	+1,246	New	+$272K	0.01%	557

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Allstate Investment Management's CRL Position: Q4 2022 in Review

Allstate Investment Management opened a new position in Charles River Laboratories (CRL) in Q4 2022: 1,246 shares worth $272K. The stake represents 0.01% of the portfolio and ranks #557 among its holdings.

627 funds tracked by Wall St. Rank hold CRL as of Q4 2022.

Allstate Investment Management held 1,246 shares of Charles River Laboratories worth $272K as of Q4 2022.
Charles River Laboratories was a new Allstate Investment Management position in Q4 2022.
Charles River Laboratories made up 0.01% of Allstate Investment Management's portfolio in Q4 2022, its #557 holding.
627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2022.

Based on Allstate Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.